Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: Report of the font clinical trial group Clinical Research

BMC Nephrology

Volumn 16, Issue 1, 2015, Pages

  Trachtman, Howard ^a   Vento, Suzanne ^a   Herreshoff, Emily ^b   Radeva, Milena ^c   Gassman, Jennifer ^c   Stein, Daniel T ^d   Savin, Virginia J ^e   Sharma, Mukut ^e   Reiser, Jochen ^f   Wei, Changli ^f   Somers, Michael ^g   Sr Vastava, Tarak ^h   Gipson, Debbie S ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g Metabolism and Diabetes   (United States)

^h CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Adalimumab; Antifibrotic; FSGS; Galactose; Permeability factors; Renoprotective

Indexed keywords

ADALIMUMAB; ATORVASTATIN; CREATININE; GALACTOSE; LISINOPRIL; LOSARTAN; UROKINASE RECEPTOR; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADOLESCENT; ADULT; ALLERGY; ANOREXIA; ARTICLE; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL ARTICLE; CONGENITAL MALFORMATION; CONTROLLED STUDY; COUGHING; CREATININE URINE LEVEL; DEHYDRATION; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; EDEMA; FATIGUE; FEMALE; FOCAL GLOMERULOSCLEROSIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEADACHE; HOSPITALIZATION; HUMAN; HUMAN CELL; HYPOTENSION; INFECTION; KIDNEY DISEASE; MALE; MUSCULOSKELETAL DISEASE; NAUSEA; OUTCOME ASSESSMENT; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHYSICAL DISABILITY; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING; BLOOD; CLINICAL TRIAL; DRUG RESISTANCE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; PATHOPHYSIOLOGY; YOUNG ADULT;

ADALIMUMAB; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG RESISTANCE; FEMALE; GALACTOSE; GLOMERULAR FILTRATION RATE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PROTEINURIA; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 84937468069     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/s12882-015-0094-5     Document Type: Article

References (31)

1. Kiffel J, Rahimzada Y, Trachtman H. Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients. Adv Chronic Kidney Dis. 2011;18(5):332-8.
2. : Causes and pathogenesis of focal segmental glomerulosclerosis. Nat Rev Nephrol 2014 Dec 2. doi: 10.1038/nrneph.2014.216. [Epub ahead of print]
3. Sadowski CE, Lovric S, Ashraf S, Pabst WL, Gee HY, Kohl S, et al; the SRNS Study Group, Hildebrandt F: A single-gene cause in 29.5 % of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2014 Oct 27. pii: ASN.2014050489. [Epub ahead of print]
4. Schell C, Huber TB. New players in the pathogenesis of focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2012;27(9):3406-12.
5. Sethna CB, Gipson DS. Treatment of FSGS in Children. Adv Chronic Kidney Dis. 2014;21(2):194-9.
6. Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 2011;80(8):868-78.
7. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005;16(4):1061-8.
8. Gipson DS, Chin H, Presler TP, Jennette C, Ferris ME, Massengill S, et al. Differential risk of remission and ESRD in childhood FSGS. Pediatr Nephrol. 2006;21(3):344-9.
9. Leca N. Focal segmental glomerulosclerosis recurrence in the renal allograft. Adv Chronic Kidney Dis. 2014;21(5):448-52.
10. Trachtman H, Vento S, Gipson D, Wickman L, Gassman J, Joy M, et al. Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. BMC Nephrol. 2011;12:8. doi: 10.1186/1471-2369-12-8.
11. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-71.
12. Savin VJ, McCarthy ET, Sharma R, Charba D, Sharma M. Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res. 2008;151(6):288-92. doi: 10.1016/j.trsl.2008.04.001.
13. De Smet E, Rioux JP, Ammann H, Déziel C, Quérin S. FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. Nephrol Dial Transplant. 2009;24(9):2938-40.
14. Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, et al. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis. 2010;55(1):50-60.
15. Schadewaldt P, Hammen HW, Loganathan K, Bodner-Leidecker A, Wendel U. Analysis of concentration and 13C Enrichment of D-Galactose in human plasma. Clin Chem. 2000;46(5):612-9.
16. Savin VJ, Sharma R, Lovell HB, Welling DJ. Measurement of albumin reflection coefficient with isolated rat glomeruli. J Am Soc Nephrol. 1992;3:1260-9.
17. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17(8):952-60.
18. Liu P, John C, Marcel D. Phase II Selection Designs, Handbook of Statistics in Clinical Oncology. Chapter 6th ed. 2001. p. 119-27.
19. Simon R, Wittes R. Ellenberg: Randomized phase II clinical trials. Cancer Treatment Rep. 1985;69:1375-81.
20. Buyse M. Randomized designs for early trials of new cancer treatments-An overview. Drug Inform J. 2000;34:387-96.
21. Sgambat K, Banks M, Moudgil A. Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2013;28(11):2131-5.
22. McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010;5(11):2115-21.
23. Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol. 2012;23(12)):2051-9.
24. Delville M, Sigdel TK, Wei C, Li J, Hsieh SC, Fornoni A, et al. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med. 2014;6(256):256ra-136. doi: 10.1126/scitranslmed.3008538.
25. Strippoli GF, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol. 2004;15(2):411-9.
26. Inrig JK, Califf RM, Tasneem A, Vegunta RK, Molina C, Stanifer JW, et al. The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov. Am J Kidney Dis. 2014;63(5):771-80.
27. Ferris M, Norwood V, Radeva M, Gassman JJ, Al-Uzri A, Askenazi D, et al. Patient recruitment into a multicenter randomized clinical trial for kidney disease: report of the focal segmental glomerulosclerosis clinical trial (FSGS CT). Clin Transl Sci. 2013;6(1):13-20.
28. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275-85.
29. Thyagarajan V, Norman H, Alexander KA, Napalkov P, Enger C. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients. Semin Arthritis Rheum. 2012;42(3):223-33.
30. Chow SC. Adaptive clinical trial design. Ann Rev Med. 2014;65:405-15.
31. Duan N, Kravitz RL, Schmid CH. Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research. J Clin Epidemiol. 2013;66(8 Suppl):S21-8.